These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

813 related items for PubMed ID: 27138377

  • 1. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
    Thavikulwat AC, Tomson TT, Knight BP, Bonow RO, Choudhury L.
    J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
    [Abstract] [Full Text] [Related]

  • 2. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K, Suzuki A, Shiga T, Minami Y, Arai K, Ashihara K, Shoda M, Hagiwara N.
    BMC Cardiovasc Disord; 2021 Feb 19; 21(1):106. PubMed ID: 33607967
    [Abstract] [Full Text] [Related]

  • 3. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczyńska-Mazuruk R, Ruzyłło W, Szwed H.
    J Cardiovasc Electrophysiol; 2010 Aug 01; 21(8):883-9. PubMed ID: 20132378
    [Abstract] [Full Text] [Related]

  • 4. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA, Howes AJ, Boland P, Shen XS, Stuckless S, Young TL, Curtis F, Collier A, Parfrey PS, Connors SP.
    Circ Arrhythm Electrophysiol; 2016 Mar 01; 9(3):. PubMed ID: 26966288
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
    Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, Rosenfeld L, Mitiku TY, Cooper JM, Mehta D, Greenspon AJ, Ortman M, Delurgio DB, Valadri R, Narasimhan C, Swapna N, Singh JP, Danik S, Markowitz SM, Almquist AK, Krahn AD, Wolfe LG, Feinstein S, Ellenbogen KA.
    Europace; 2013 Mar 01; 15(3):347-54. PubMed ID: 23002195
    [Abstract] [Full Text] [Related]

  • 6. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants.
    Rowin EJ, Burrows A, Madias C, Estes NAM, Link MS, Maron MS, Maron BJ.
    Circ Arrhythm Electrophysiol; 2020 Oct 01; 13(10):e008123. PubMed ID: 32897759
    [Abstract] [Full Text] [Related]

  • 7. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P.
    JAMA; 2007 Jul 25; 298(4):405-12. PubMed ID: 17652294
    [Abstract] [Full Text] [Related]

  • 8. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P.
    Circ Arrhythm Electrophysiol; 2018 Apr 25; 11(4):e005820. PubMed ID: 29625970
    [Abstract] [Full Text] [Related]

  • 9. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P, Katsanos S, Joyce E, VAN DEN Brink OV, Atsma DE, Schalij MJ, Bax JJ, Delgado V, Marsan NA.
    J Cardiovasc Electrophysiol; 2015 May 25; 26(5):547-55. PubMed ID: 25648421
    [Abstract] [Full Text] [Related]

  • 10. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.
    Schaer B, Kühne M, Reichlin T, Osswald S, Sticherling C.
    Europace; 2016 Feb 25; 18(2):227-31. PubMed ID: 26063686
    [Abstract] [Full Text] [Related]

  • 11. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir A, Dorian P, Rakowski H, Care M, Spears D.
    Heart Rhythm; 2021 Jan 25; 18(1):63-70. PubMed ID: 32800967
    [Abstract] [Full Text] [Related]

  • 12. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA, Link MS, Semsarian C, Shen WK, Estes NA, Maron MS, Haas TS, Formisano F, Boriani G, Spirito P, Maron BJ.
    Heart Rhythm; 2013 Feb 25; 10(2):214-8. PubMed ID: 23041573
    [Abstract] [Full Text] [Related]

  • 13. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J, Bader YH, Maron MS, Rowin EJ, Link MS.
    J Am Heart Assoc; 2016 Feb 12; 5(2):. PubMed ID: 26873684
    [Abstract] [Full Text] [Related]

  • 14. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F, Gimeno JR, Payá E, García-Alberola A, Pérez-Alvarez L, Fernández X, de la Morena G, Sogorb F, Castro-Beiras A, Valdés M, Martínez JG, Monserrat L.
    Rev Esp Cardiol; 2006 Jun 12; 59(6):537-44. PubMed ID: 16790196
    [Abstract] [Full Text] [Related]

  • 15. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
    Francia P, Adduci C, Palano F, Semprini L, Serdoz A, Montesanti D, Santini D, Musumeci B, Salvati A, Volpe M, Autore C.
    J Cardiovasc Electrophysiol; 2015 Aug 12; 26(8):893-899. PubMed ID: 25996259
    [Abstract] [Full Text] [Related]

  • 16. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS.
    J Am Coll Cardiol; 2013 Apr 09; 61(14):1527-35. PubMed ID: 23500286
    [Abstract] [Full Text] [Related]

  • 17. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
    Nazer B, Dale Z, Carrassa G, Reza N, Ustunkaya T, Papoutsidakis N, Gray A, Howell SJ, Elman MR, Pieragnoli P, Ricciardi G, Jacoby D, Frankel DS, Owens A, Olivotto I, Heitner SB.
    Heart Rhythm; 2020 Jul 09; 17(7):1107-1114. PubMed ID: 32084597
    [Abstract] [Full Text] [Related]

  • 18. Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.
    Zhou Y, Zhao S, Chen K, Hua W, Su Y, Chen S, Liang Z, Xu W, Zhang S.
    BMC Cardiovasc Disord; 2019 Oct 21; 19(1):230. PubMed ID: 31638918
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J, Luria D, Gurevitz O, Bar-Lev D, Eldar M, Glikson M.
    Europace; 2014 Feb 21; 16(2):227-34. PubMed ID: 24108231
    [Abstract] [Full Text] [Related]

  • 20. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients.
    Dichtl W, Wolber T, Paoli U, Brüllmann S, Stühlinger M, Berger T, Spuller K, Strasak A, Pachinger O, Haegeli LM, Duru F, Hintringer F.
    Clin Cardiol; 2011 Jul 21; 34(7):433-6. PubMed ID: 21678454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.